利纳西普治疗复发性心包炎停药策略与复发率比较分析
该回顾性队列研究纳入53例难治性复发性心包炎患者,比较利纳西普突然停药与逐渐减量策略的复发率。结果显示突然停药组复发率82%显著高于减量组37%(p=0.042),秋水仙碱预防可延迟复发时间60.7周,长期治疗耐受良好。
要点
- 利纳西普突然停药后复发率高达82%,逐渐减量可降低至37%
- 减量方案为从每周逐渐过渡到每两周、每月直至停药
- 停用利纳西普后使用秋水仙碱可平均延迟复发60.7周
核心结论
- 长期利纳西普治疗超过18-24个月可使复发性心包炎获得持续缓解,但撤药后约三分之二患者复发。
- 逐渐减量策略相比突然停药与相对较低的疾病复发风险相关。
研究设计与样本
- 回顾性队列研究,在克利夫兰诊所心包疾病中心开展。
- 纳入53例对一线治疗难治的复发性心包炎成人患者,接受利纳西普至少12个月(中位24个月),症状和心脏MRI晚期钆增强改善。
- 主要结局为突然停药与逐渐减量(从每周到每两周、每月直至停止)后的复发率比较。
主要发现
- 53例患者中女性占61.8%,平均年龄54.6±14.17岁。
- 34例(62%)突然停药,19例(35%)经医患共同决策后逐渐减量。
- 突然停药组复发率82%,减量组37%(p=0.042)。
- 停用利纳西普后使用秋水仙碱与平均复发时间延迟60.7周相关。
- 80%的复发患者重新启用利纳西普;长期治疗耐受良好。
临床怎么用
- 对于接受利纳西普治疗的复发性心包炎患者,停药时应考虑逐渐减量而非突然停药。
- 停用利纳西普后可考虑使用秋水仙碱预防以延迟复发。
- 长期利纳西普治疗超过18-24个月可维持疾病缓解,但需权衡停药后复发风险。
局限性
- 回顾性研究设计,样本量较小(53例),来自单中心。
- 需更大规模、多中心、长期随访研究以明确最佳治疗疗程和标准化停药方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND/OBJECTIVES: Rilonacept (RI), an interleukin (IL)-1α/β cytokine trap, is a biological treatment to prevent recurrence in recurrent pericarditis (RP). Discontinuation of RI in patients after 18 months with RP has been associated with a higher rate of RP. We aimed to propose a preliminary strategy for stopping Rl in select patients and evaluate their long-term outcomes. METHODS: We conducted a retrospective cohort study at the pericardial disease centre at Cleveland Clinic, Ohio. Adults included had RP refractory to first-line therapies, receiving Rl for at least 12 months (median duration 24 months) with improvement in symptoms and late gadolinium enhancement on cardiac MRI. The primary outcome was recurrence of RP post abrupt Rl discontinuation versus slow taper (gradual decrease in Rl frequency from weekly, to bimonthly, to monthly and then cessation). We also evaluated the effects of colchicine prophylaxis at the end of Rl therapy, time to recurrence and the overall safety profile of long-term Rl therapy. RESULTS: A total of 53 patients were included in the study (61.8% female; mean age 54.6±14.17 y), of which 34 (62%) discontinued RI abruptly/without tapering and 19 (35%) underwent a RI taper after shared decision making with their clinician. A higher percentage of recurrent cases was observed in the abrupt cessation arm (82%) versus the taper arm (37%) (p=0.042). Treatment with colchicine post-completion of Rl therapy was associated with delaying the average time to flare by 60.7 weeks. Most patients (80%) resumed Rl after a recurrence. Long-term Rl therapy was well-tolerated during the follow-up period. CONCLUSIONS: Long-term Rl therapy beyond 18-24 months leads to sustained disease remission in RP, and therapy withdrawal is associated with a recurrence in two-thirds of patients. A strategy that involves a gradual taper of RI therapy appears to be associated with a relatively lower risk of disease recurrence compared with discontinuation without tapering. Larger-scale, multicentre studies with extended follow-up periods are warranted to elucidate optimal treatment durations and to establish standardised cessation protocols.
引用
- Saraswati U, Bhalla JS, Tereshchenko LG, et al. Comparative analysis of recurrence rates following various cessation strategies for rilonacept in recurrent pericarditis. Heart. 2026. PMID: 41115771. doi:10.1136/heartjnl-2024-325515
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。